Moderna Considers Price of $110-$130 for Covid-19 Vaccine
Moderna Inc.
said it is considering pricing its Covid-19 vaccine in a range of $110 to $130 per dose in the U.S. when it shifts from government contracting to commercial distribution of the shots.
The range is similar to the one
Pfizer Inc.
said in October it was considering for the Covid-19 vaccine it developed with
BioNTech SE.
“I would think this type of pricing is consistent with the value” provided by the vaccine, Moderna Chief Executive Officer
Stephane Bancel
said in an interview Monday on the sidelines of the J.P. Morgan Healthcare Conference in San Francisco.
The expected price for commercial insurers would be significantly higher than the per-dose cost in Moderna’s supply contracts with the federal government. Moderna’s updated booster shots cost about $26 per dose in a federal supply contract signed in July 2022. The original vaccine cost about $15 to $16 per dose in earlier supply contracts.
To date, the federal government has purchased all doses of Covid-19 vaccines and made them available at no cost to consumers. U.S. officials have said that after the supply secured under federal contracts runs out, companies should switch to standard commercial distribution.
Moderna is in discussions with hospital systems, pharmacies and pharmacy-benefit managers to line up distribution of its vaccine ahead of a potential fall booster shot campaign, Mr. Bancel said.
Any booster shots distributed in the fall may be updated to match circulating variants of the coronavirus, Mr. Bancel said.
Even at higher per-dose pricing, sales of Moderna’s Covid-19 vaccine are expected to decline. The Cambridge, Mass., company said Monday it expects minimum Covid-19 vaccine sales of about $5 billion for 2023, with the potential for more. For full-year 2022, it recorded about $18.4 billion in Covid-19 vaccine sales.
The company is increasing its focus on potential new products beyond the Covid-19 vaccine, such as a vaccine for respiratory syncytial virus, or RSV. Moderna expects to report results from a large study for its RSV vaccine soon, Mr. Bancel said.
Write to Peter Loftus at [email protected]
Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Moderna Inc.
said it is considering pricing its Covid-19 vaccine in a range of $110 to $130 per dose in the U.S. when it shifts from government contracting to commercial distribution of the shots.
The range is similar to the one
Pfizer Inc.
said in October it was considering for the Covid-19 vaccine it developed with
BioNTech SE.
“I would think this type of pricing is consistent with the value” provided by the vaccine, Moderna Chief Executive Officer
Stephane Bancel
said in an interview Monday on the sidelines of the J.P. Morgan Healthcare Conference in San Francisco.
The expected price for commercial insurers would be significantly higher than the per-dose cost in Moderna’s supply contracts with the federal government. Moderna’s updated booster shots cost about $26 per dose in a federal supply contract signed in July 2022. The original vaccine cost about $15 to $16 per dose in earlier supply contracts.
To date, the federal government has purchased all doses of Covid-19 vaccines and made them available at no cost to consumers. U.S. officials have said that after the supply secured under federal contracts runs out, companies should switch to standard commercial distribution.
Moderna is in discussions with hospital systems, pharmacies and pharmacy-benefit managers to line up distribution of its vaccine ahead of a potential fall booster shot campaign, Mr. Bancel said.
Any booster shots distributed in the fall may be updated to match circulating variants of the coronavirus, Mr. Bancel said.
Even at higher per-dose pricing, sales of Moderna’s Covid-19 vaccine are expected to decline. The Cambridge, Mass., company said Monday it expects minimum Covid-19 vaccine sales of about $5 billion for 2023, with the potential for more. For full-year 2022, it recorded about $18.4 billion in Covid-19 vaccine sales.
The company is increasing its focus on potential new products beyond the Covid-19 vaccine, such as a vaccine for respiratory syncytial virus, or RSV. Moderna expects to report results from a large study for its RSV vaccine soon, Mr. Bancel said.
Write to Peter Loftus at [email protected]
Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.